FMEDFidelity Disruptive Medicine ETF

Grow my money6y track recordRanked #1,746 of 2,960 in this goal

Seeks long-term growth of capital.

By Fidelity Investments · Launched 2020

Annual Cost

0.50%

#2,576 of 5,562 · average

Fund Size

$41M

#3,750 of 5,562 · small

Return (1Y)Goal

+11.7%

Track Record

6 years

#2,086 of 5,562 · seasoned

Performance

Total-return NAV · USD

Growth of $10,000

$11,185+11.9%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Strategy

Active selection

Sector

Health care

Focus

General Innovation

What it actually holds

By weight

Concentration

Top 10 holdings = 40.2% of fundmoderately concentrated

Fidelity Revere Street Trust

5.4%

EXACT SCIENCES CORP

5.0%

BOSTON SCIENTIFIC CORP

4.5%

ARGENX SE

4.4%

ALNYLAM PHARMACEUTICALS INC

4.2%

COGENT BIOSCIENCES INC

3.8%

UCB SA

3.5%

DANAHER CORP

3.3%

INSULET CORP

3.1%

INTUITIVE SURGICAL INC

2.9%

Asset allocation

Stocks

99.7%

Cash

10.7%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

19.3%Moderate

Year-on-year price swings

Max drawdown

-21.8%Moderate

Worst peak-to-trough loss

Sharpe (3Y)

-0.05Below average

Sortino (3Y)

-0.07Moderate downside risk

Where to buy

Listing

Exchange: NASDAQ Global Market, NASDAQ Global Select Market

Full fund details

Objective: Seeks long-term growth of capital.
Strategy: Invests primarily in securities of disruptive medicine companies, focusing on innovative developments that could disrupt incumbents. Uses fundamental analysis to select investments across sectors, concentrating in health care, and may include both growth and value stocks.
Inception date: April 16, 2020
Fund family: Fidelity Investments